Oct 09, 2017 09:25 AM IST | Source: Moneycontrol.com
Cadila Healthcare rises 1% on USFDA nod for Amitriptyline Hydrochloride tablets
The drug is used to treat depression and will be manufactured at group's formulations manufacturing facility at SEZ, Ahmedabad.
Moneycontrol News
Shares of Cadila Healthcare rose 1 percent intrady Monday as it has received USFDA approval for Amitriptyline Hydrochloride tablets.
Zydus Cadila has received the final approval from the USFDA to market Amitriptyline Hydrochloride Tablets USP in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg.
The drug is used to treat depression and will be manufactured at group's formulations manufacturing facility at SEZ, Ahmedabad.
The group has now more than 160 approvals and so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
At 09:19 hrs Cadila Healthcare was quoting at Rs 504.80, up Rs 4.25, or 0.85 percent on the BSE.
Posted by Rakesh Patil
Stumps 
